<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LATANOPROST <img border="0" src="../images/pr.gif"/></span><br/>(la-tan'o-prost)<br/><span class="topboxtradename">Xalatan<br/></span><b>Classifications:</b> <span class="classification">eye preparation</span>; <span class="classification">prostaglandin</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.005% solution</p>
<h1><a name="action">Actions</a></h1>
<p>Prostaglandin analog that is thought to reduce intraocular pressure (IOP) by increasing the outflow of aqueous humor.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces elevated intraocular pressure in patients with open-angle glaucoma.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of open-angle glaucoma, ocular hypertension and elevated intraocular pressure (IOP).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to latanoprost or another component in the solution; pregnancy (category C); intraocular infection; conjunctivitis.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation; active intraocular inflammation such as: iritis or uveitis; patients at risk for macular edema; hepatic or renal
         impairment. Safety and effectiveness in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Glaucoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> 1 drop in affected eye(s) q.d. in evening<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Installation</span><br/><ul>
<li>Ensure that contact lenses are removed prior to installation and not reinserted for 15 min after installation.</li>
<li>Apply only to affected eye(s). Ensure that only one drop is instilled.</li>
<li>Do not allow tip of dropper to touch eye.</li>
<li>Wait at least 5 min before/after instillation of other eye drops.</li>
<li>Refrigerate at 2°8° C (36°46° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Headaches, asthenia, flu-like symptoms. <span class="typehead">GI:</span> Abnormal liver function tests. <span class="typehead">Skin:</span> Rash. <span class="typehead">Special Senses:</span> <span class="speceff-common">Conjunctival hyperemia, growth of eyelashes, ocular pruritus,</span> ocular dryness, visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the periocular skin,
      blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, and eyelash darkening, eye discharge,
      tearing, photophobia, allergic conjunctivitis, increases in iris pigmentation (brown pigment), conjunctival edema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Precipitation may occur if mixed with eye drops containing <b>thimerosal;</b> space other <span class="classification">eye preparations</span> at least 5 min apart. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorbed through the cornea. <span class="typehead">Onset:</span> 34 h. <span class="typehead">Peak IOP reduction:</span> 812 h. <span class="typehead">Distribution:</span> Minimal systemic distribution. <span class="typehead">Metabolism:</span> Hydrolyzed in aqueous humor to active form. <span class="typehead">Elimination:</span> Renally excreted. <span class="typehead">Half-Life:</span> 17 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Withhold eye drops and notify physician if acute intraocular inflammation (iritis or uveitis) or external eye inflammation
            are noted.
         </li>
<li>Note that increased pigmentation of the iris and eyelid, and additional growth of eyelashes on the treated eye are adverse
            effects that may develop gradually over months to years.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician immediately if any ocular reaction occurs, especially conjunctivitis and lid reactions.</li>
<li> 							Note: Increased pigmentation of the iris and eyelid, and additional growth of eyelashes on the treated eye, are possible adverse
            effects of this drug. Persons with light colored eyes receiving treatment to one eye may develop a darker eye. 						
         </li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>